



PEACCEL AND POLYCLONE SIGN MoU TO OFFER PROTEIN ENGINEERING SERVICES

Cambridge, MA, 5th Nov 2013 – Peacel, a Bio-IT company that provides predictive solutions for protein engineering services, today signed a Memorandum of Understanding with Polyclone Bioservices to utilize Polyclone’s *in silico* enzyme engineering framework (eEF) to strengthen its protein engineering services. Collaborations under this MoU are focused on offering specifically enzyme engineering services to optimize enzymes for better activity, stability and specificity under process conditions.

“Peacel’s vision is to command a leading commercial presence in predictive solutions for directed molecular evolution and protein engineering through its unique sets of algorithms and knowhow. Polyclone’s outstanding technology for enzyme engineering services is perfectly complementary to our services. We believe our partnership with Polyclone is a great opportunity to leverage our respective commercial presence in the fast growing enzyme engineering industry” said Dr. Frédéric CADET, VP - Business Development for Peacel.

“Polyclone’s in-depth expertise in molecular modeling and simulation complements perfectly our own expertise on semi-rational design and rational screening. We have very good traction with their scientists. Altogether, this provides us the opportunity to offer a fully integrated solution to the enzyme engineering market” said Dr. Bernard Offmann, VP – Research for Peacel.

“Our enzyme engineering framework - eEF is a smart integration of proprietary algorithms and processes for high throughput and high confidence predictions of enzyme & protein modifications for desired properties. The solution integrates computational library design, directed evolution and statistical modeling of sequence–function relationships while considering the intermediary stages of enzyme-substrate interaction to achieve its goals” said Mr. Naveen Kulkarni, CEO of Polyclone and added that “with the recognition of importance of molecular dynamics (MD) in this year’s Nobel prize for chemistry, it has further affirmed our approach, and the extensive experience that Peacel brings to this collaboration, provides unparalleled advantage to our customers in solving highly complex enzyme productivity issues and we hope to contribute to better financial outcomes combining this with a greener objective”.

About Peacel: Peacel is a service company specialized in protein engineering and design and synthetic biology. The company provides predictive product discovery solutions to biotech & pharmaceutical companies and academic research units. Its unique expertise and in-silico discovery platform are dedicated to reduce cost, time and risks associated with engineering of protein therapeutics, industrial enzymes and synthetic pathways. Peacel also develops a



horizontal business by early partnering for co-development of industrial enzymes or protein therapeutics. The company operates in both Paris (France), and Cambridge (MA, USA).

About Polyclone: Polyclone is an integrated biology company with expertise in molecular, cell & computational biology catering to the bio-pharma & healthcare industries. Polyclone's innovative solutions based on synergistic combination of *in silico* & *in vitro* approaches aim to facilitate nucleic acid studies, peptide analysis & design, protein & enzyme engineering and small molecule research in addition to providing technology support for cell culture studies and molecular diagnostics. Polyclone is headquartered in Bangalore, India with presence in Europe and US.

For further information please contact:

Peacel Inc.

Dr. Frédéric CADET

Vice President Business Development

frederic.cadet@peacel.com

Polyclone Bioservices Pvt. Ltd.

Mr. Praveen Rajendra

Chief Operating Officer

praveen.r@polyclonebio.com

###